T BERL, AS BERNS, WE HUFFER, K … - Annals of Internal Medicine, 1978 - Am Coll Physicians 1,25 dihydroxycholecalciferol [1,25(OH) 2 D 3 ] was studied in a double-blind
controlled fashion in patients on chronic dialysis. Serum calcium was unchanged
in 16 patients on vitamin D 3 (D 3 ) (400 to 1200 IU/day). In 15 patients ... Cited by 70 - Related articles - All 2 versions
LR Baker, JW Muir, VL Sharman, SM Abrams, … - Clinical nephrology, 1986 - ncbi.nlm.nih.gov We report on a 5-year, prospective, double-blind trial of 1,25
dihydroxycholecalciferol (calcitriol) versus placebo in 76 hemodialysis patients
without biochemical or radiological evidence of bone disease. Calcitriol, 1 ... Cited by 34 - Related articles - All 2 versions
- ►nih.gov [PDF] DE Memmos, JB Eastwood, LB Talner, PE … - British Medical Journal, 1981 - bmj.com 8Saunders L, Natunen T. A four parameter model for oral drug absorption. J Pharm
Pharmacol 1976;28:572-9. 9 Evans GH, Shand DG. Disposition of propranolol. V.
Drug accumulation and steady-state concentrations during chronic oral ... Cited by 36 - Related articles - All 4 versions
Y Tsukamoto, M Nomura, Y Takahashi, Y … - Nephron, 1991 - content.karger.com Many hemodialysis patients are still suffering from secondary
hyperparathyroidism although 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) has
been used to treat renal osteodystrophy for the last two decades. The main ... Cited by 101 - Related articles - All 6 versions
LD Quarles, GA Davidai, SJ Schwab, DW … - Kidney Int, 1988 - nature.com Oral calcitriol and calcium: An efficient therapy for uremic
hyperparathyroidism. Therapy with orally administered calcitriol often does not
adequately control the biochemical manifestations of secondary ... Cited by 63 - Related articles - All 4 versions
H Muramoto, K Haruki, A Yoshimura, N Mimo, … - Nephron, 1991 - content.karger.com Intermittent oral administration of high dose 1,25(OH) 2 vitamin D 3 was
conducted in 7 patients associated with treatment-resistant secondary
hyperparathyroidism (2nd HPT) on hemodialysis (HD) therapy. Each patient ... Cited by 32 - Related articles - All 6 versions
M Gallieni, D Brancaccio, P Padovese, D Rolla … - Kidney international, 1992 - ncbi.nlm.nih.gov 1: Kidney Int. 1992 Nov;42(5):1191-8. Low-dose intravenous calcitriol treatment
of secondary hyperparathyroidism in hemodialysis patients. ... Cited by 81 - Related articles - BL Direct - All 3 versions
- ►oxfordjournals.org M Hayashi, Y Tsuchiya, Y Itaya, T Takenaka, … - Nephrology Dialysis Transplantation, 2004 - ERA-EDTA Results. Treatment was discontinued for various reasons in nine patients in each
group, but no serious side effects were observed in either group. The numbers of
cases reaching the first end point were not significantly different between ... Cited by 17 - Related articles - BL Direct - All 7 versions
WJ Johnson, JT McCarthy, JA van Heerden, S … - The American journal of medicine, 1988 - Elsevier In 61 hemodialysis patients undergoing subtotal parathyroidectomy, there was a
good correlation between the preoperative serum immunoreactive parathyroid
hormone value (iPTH) and the weight of parathyroid tissue removed ... Cited by 53 - Related articles - All 4 versions
IB Salusky, RN Fine, H Kangarloo, R Gold, L … - Kidney int, 1987 - nature.com "High–dose" calcitriol for control of renal osteodystrophy in children on
CAPD. High doses of calcitriol were used prospectively for 11 to 29 months to
raise serum calcium levels in an effort to control renal osteodystrophy in ... Cited by 40 - Related articles - All 4 versions
